CE-Ventures, the corporate venture capital platform of Crescent Enterprises, has invested $38 million in Freya Biosciences in a Series A funding round. Freya Biosciences is a biotech company specializing in women’s health, particularly in microbial immunotherapies for reproductive health conditions. This funding will support the development of Freya’s lead drug candidate, an investigational vaginal microbial immunotherapeutic targeting infertility in women. The funding will also drive the evolution of Freya’s data science platform, focusing on deep microbiome sequencing and immune biomarker profiling. The investment is part of CE-Ventures’ commitment to exploring innovative fields and its belief in the potential of microbial immunotherapies. Other investors in the funding round include Sofinnova Partners, OMX Ventures, and Angelini Ventures.
$38 Million Funding Boost for Breakthroughs: Freya Biosciences Secures CE-Ventures’ Support
Latest from Blog
Startup Spring Ahead: Fintech and Regtech Outlook from Early-stage VC
TLDR: Early-stage VC Dirk Steller predicts a ‘startup spring’ ahead, particularly in fintech and regtech sectors. Funding in Australia is up 6% in Q1 2024, with a mature startup market seeing bigger
Crypto Sector Raises $317M in Venture Capital Funds in June
TLDR: In early June, the crypto sector secured $317 million in venture capital deals. This funding is a positive sign for the industry and demonstrates continued investor interest in the space. Article
Paradigm Raises $850M, Solidifies Status as Top VC Powerhouse
Article Summary TLDR: Key Points: Paradigm raised $850 million for its third fund, showing strength in venture capital in the crypto space. While still below previous high levels, the funding round indicates
Tech Trending: Startup Rumblings & Global News in Issue 133
TLDR: Top venture capital firms are crucial for the success of tech startups. J.P. Morgan raises over $500 million for its first biotech venture capital fund. In the latest tech trends and
New Name: Venture Capital Firm Changing Identity Post-Founder’s Departure
TLDR: London-based venture capital firm Hambro Perks is set to change its name to Salica Investments following the death and resignation of its co-founders. The new name, Salica Investments, signifies reliability and